PROTEXI Cancer Vaccine Harnesses COVID‑19 Immune Memory for Tumor Treatment
Scientists from Celloram Inc., University Hospitals and Case Western Reserve University in Cleveland have created PROTEXI, a dendritic‑cell cancer vaccine platform that redirects pre‑existing antiviral immunity from SARS‑CoV‑2 infection or vaccination toward tumors. The vaccine pairs tumor‑specific antigens with spike‑protein epitopes, activating CD4+ helper T‑cells that boost CD8+ cytotoxic responses. In preclinical mouse models of melanoma and breast cancer, PROTEXI slowed tumour growth, improved survival and converted immune‑cold tumours into ones recognizable by the immune system. Effectiveness was also shown in humanised mice using immune cells from COVID‑19‑vaccinated donors, and the platform worked synergistically with other immunotherapies such as a TGF‑β inhibitor. The research, published in Nature Communications on 27 July 2026, paves the way for first‑in‑human trials in sarcoma patients.
Entities: Case Western Reserve University · Celloram Inc. · PROTEXI · PROTEXI · SARS‑CoV‑2 · SARS‑CoV‑2 spike protein · University Hospitals
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] PROTEXI synergizes with other immunotherapies to further reduce tumor burden. (faea8099-4fa7-49e0-a1f4-c91591e143bc)
- [● 5 SOURCES] PROTEXI leverages pre‑existing antiviral immune memory from SARS‑CoV‑2 infection or vaccination. (Scientists Turn COVID-19 Immune Memory into a Powerful New Ally Against Cancer; Novel Dendritic Cell Vaccine Redirects)
- [● 5 SOURCES] Scientists from Celloram Inc., University Hospitals and Case Western Reserve University developed the PROTEXI dendritic‑cell cancer vaccine platform. (PROTEXI Cancer Vaccine Platform Based On SARS‑CoV‑2 Immune Memory; Novel Dendritic Cell Vaccine Redirects Viral Memory)
- [● 5 SOURCES] In preclinical mouse models of melanoma and breast cancer, PROTEXI slowed tumor growth. (Scientists Turn COVID-19 Immune Memory; Novel Dendritic Cell Vaccine)
- [● 4 SOURCES] The study describing PROTEXI was published in Nature Communications on 27 July 2026. (new)
- [● 5 SOURCES] PROTEXI showed effectiveness in humanized mouse models using immune cells from COVID‑19‑vaccinated donors. (Scientists Turn COVID-19 Immune Memory; Novel Dendritic Cell Vaccine)
- [● 5 SOURCES] Researchers plan to begin first‑in‑human clinical trials of PROTEXI in sarcoma patients. (Scientists Turn COVID-19 Immune Memory; PROTEXI Cancer Vaccine Platform)
- [● 5 SOURCES] PROTEXI transformed immune‑cold tumors into ones recognizable by the immune system. (Scientists Turn COVID-19 Immune Memory; Novel Dendritic Cell Vaccine)
- [● 2 SOURCES] PROTEXI generated durable antitumor memory and enhanced CD8+ T‑cell responses via CD4+ helper T‑cell memory. (new)
- [● 4 SOURCES] PROTEXI uses SARS‑CoV‑2 Spike protein epitopes to boost CD4+ helper T‑cell immunity and enhance CD8+ cytotoxic T‑cell anti‑tumor responses. (new)
- [● 5 SOURCES] PROTEXI improved survival in preclinical mouse models of melanoma and breast cancer. (Scientists Turn COVID-19 Immune Memory; Novel Dendritic Cell Vaccine)
- [● 2 SOURCES] The research on PROTEXI was published in Nature Communications on 27 July 2026. (new)